Cell and Gene Therapy Catapult launches new network for the advanced therapies industry in Scotland

The Cell and Gene Therapy Catapult (CGT Catapult), with support from Scottish Enterprise, Scotland’s national economic development agency, today announces the launch of a new cooperative network to foster collaboration and boost the sharing of knowledge and expertise within the advanced therapies industry across the north of the UK.

The ‘Scottish Advanced Therapy Medicinal Products (ATMP) and Vaccines Network’ will coordinate events, talks from industry leaders and networking opportunities for the advanced therapies industry. It will also develop a directory of companies working in advanced therapies in the region, including detail on their expertise and offerings. With this directory, the CGT Catapult aims to create an invaluable source of information for the industry, helping organisations gain awareness of each other’s capabilities and encourage more connections, collaborations and partnerships between academia and industry to advance the sector.

There are over 700 life sciences organisations in Scotland, employing over 41,000 people. The sector is continuing to grow, with it securing 8% growth each year since 2010 and it is on track to reach a turnover of £8 billion by 2025.[1]

With the life sciences industry in Scotland thriving, the CGT Catapult believes there is an opportunity to build an ecosystem and community in the north of the UK which facilitates crucial knowledge exchange and helps organisations connect with others, helping organisations work together to bring more potentially life changing treatments to patients.

The launch of the network follows the opening of CGT Catapult’s site in the Edinburgh BioQuarter in June 2023. These state-of-the-art laboratories and offices provide resources and technology, as well as access to industry expertise, to help cell therapy developers improve their manufacturing processes and navigate the complex regulatory requirements involved in developing and bringing their therapies to market…Read more